Using a primary culture derived from a HER2-non-amplified MET (N375S) heterozygous tongue SCC tumor (NCC-NPC7), we confirmed the increased susceptibility to HER2 inhibitors (lapatinib and afatinib), but not to crizotinib as compared to a HER2-non-amplified MET wild-type HNSCC cell line (SCC13) (Supplementary Fig. 9A). Mechanistically, crizotinib attenuated p-MET and p-Src while not affecting other kinases in NPC7 cells (Supplementary Fig. 9B). On the contrary, treatment with lapatinib and afatinib effectively abrogated kinase activities of HER2, EGFR, Akt, and ERK1/2 (Supplementary Fig. 9B). In addition, we confirmed that METN375S variant in NCC-NPC7 cells co-immunoprecipitated with HER2, and similar to that in isogenic H2170 cells (Fig. 5a), this interaction could be abolished by kinase inhibition through crizotinib or/and lapatinib treatment (Supplementary Fig. 9C). Importantly, afatinib given at 15 mg/kg daily was found to significantly improve overall survival (log-rank test; P < 0.05) over the vehicle control in immunocompromised mice engrafted with METN375S-tGFP cells (Fig. 6o). In contrast, mice engrafted with METwt-tGFP cells survived longer and did not benefit from afatinib treatment (Fig. 6n), thereby confirming the aggressiveness of N375S tumors as well as the therapeutic potential of pharmacological HER2 inhibition in these tumors.
拉帕替尼 阿法替尼 吡咯替尼 单药 |
如何高效地向肿瘤医生汇报癌痛，专家
作者：jing超
本次由靓超版主，春甜秋蜜，大海整理。审核：鹰版，陈蒙蒙教授。
北京清
术前2期，术后3A期肺鳞癌错过新辅助
2023年11月第一次肺炎抗炎治疗半月，
2024年2月年后又一次肺炎治疗后于3月初肺科医院
当母亲确诊肺癌晚期，我做了3件事帮
作者：小斐阿蓉大胜
小斐的母亲在58岁那年被确诊为肺腺癌四期，已经发生了骨转移和脑
肿瘤患者进展期如何补充营养？（3）
在进展期，有50%以上的肿瘤病人首发症状是体重丢失。与营养不良的患者相比较，营养状
求助母亲肺腺ca无有效靶点低分化PDL1
如题，母亲肺腺ca IVA 低分化 目前双肺转移 大基因panel显示无有效靶点，
只有一个tp5
显身卡
